2. Academic Validation
  3. Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells

Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells

  • Cancer Manag Res. 2017 Nov 1:9:565-572. doi: 10.2147/CMAR.S146173.
Hailun Zheng # 1 2,  Huang Hong # 1,  Lulu Zhang # 1 2,  Xiong Cai 1 2,  Meng Hu 1 2,  Yuepiao Cai 2,  Bin Zhou 1,  Jiayuh Lin 3,  Chengguang Zhao 2,  Wanle Hu 1
Affiliations

Affiliations

  • 1 Department of Coloproctology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University.
  • 2 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
  • 3 Department of Biochemistry and Molecular Biology, University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MA, USA.
  • # Contributed equally.
PMID: 29138596 DOI: 10.2147/CMAR.S146173
Abstract

Activation of the signal transducer and activator of transcription 3 (STAT3) is observed in multiple Cancer types, including gastric Cancer, and represents a potential drug target for chemotherapy. Currently, clinically available small-molecule inhibitors targeting STAT3 are lacking. Here, we report that nifuratel, an antiprotozoal and Antifungal drug, is a potent inhibitor of STAT3. We found that nifuratel significantly suppressed proliferation and induced Apoptosis of gastric Cancer cells. Studies of the mechanism of action of nifuratel indicated that it acts by inhibiting the constitutive and interleukin-6-induced STAT3 activation. Taken together, our findings demonstrate that nifuratel may be a novel, clinically accessible STAT3 Inhibitor in gastric Cancer cells.

Keywords

STAT3; drug; gastric cancer; inhibitor; nifuratel.

Figures
Products